To further investigate the effect of the difference in TXNDC12 expression among the three subtypes on glioma prognosis, we divided the samples of each subtype into TXNDC12 high-expression and low-expression groups according to the median TXNDC12 expression in the samples. Here, TXNDC12 is linked to central nervous system cancer.